ARTICLE | Clinical News

Serada gabapentin GR: Phase III started

November 8, 2010 8:00 AM UTC

Depomed began the double-blind, placebo-controlled, U.S. Phase III Breeze 3 trial to evaluate 600 mg Serada in the morning plus 1,200 mg Serada in the evening for 24 weeks in about 600 patients. Depom...